文献速递类风湿关节炎

类风湿关节炎患者联用口服糖皮质激素与质子泵抑制剂增加骨质疏松性骨折风险

Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study.
PubMed 文献 · Ann Rheum Dis · 2020-12-11

单独使用任一药物风险约增1.2倍。提示联用时应考虑骨折风险评估。

要点

  • RA患者联用口服GC与PPI当前使用时骨折风险aHR 1.60,高于单药约1.2倍。
  • 联用者中骨折风险不随PPI日剂量或使用时长增加而升高。
  • 多数单个骨折部位均与GC与PPI联用显著相关。

核心结论

  • 口服GC与PPI联用对RA患者骨质疏松性骨折风险存在交互作用,联用当前使用者的骨折风险显著高于单药使用或不用。

主要发现

  • 随访期间共发生1411例骨质疏松性骨折。
  • 与不使用相比,口服GC与PPI当前联用者骨质疏松性骨折的校正HR为1.60(95%CI 1.35–1.89)。
  • 该风险与单用口服GC或PPI约1.2倍的骨折风险在统计学上不同。
  • 多数单个骨折部位与口服GC与PPI联用显著相关。
  • 联用者中骨折风险不随PPI日剂量增高或使用时长延长而增加。

临床怎么用

  • 对同时处方口服GC与PPI的RA患者,可考虑进行骨折风险评估。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with rheumatoid arthritis (RA) commonly use oral glucocorticoids (GCs) and proton pump inhibitors (PPIs), both associated with osteoporotic fractures. We investigated the association between concomitant use of oral GCs and PPIs and the risk of osteoporotic fractures among patients with RA. METHODS: This was a cohort study including patients with RA aged 50+ years from the Clinical Practice Research Datalink between 1997 and 2017. Exposure to oral GCs and PPIs was stratified by the most recent prescription as current use (<6 months), recent use (7-12 months) and past use (>1 year); average daily and cumulative dose; and duration of use. The risk of incident osteoporotic fractures (including hip, vertebrae, humerus, forearm, pelvis and ribs) was estimated by time-dependent Cox proportional-hazards models, statistically adjusted for lifestyle parameters, comorbidities and comedications. RESULTS: Among 12 351 patients with RA (mean age of 68 years, 69% women), 1411 osteoporotic fractures occurred. Concomitant current use of oral GCs and PPIs was associated with a 1.6-fold increased risk of osteoporotic fractures compared with non-use (adjusted HR: 1.60, 95% CI: 1.35 to 1.89). This was statistically different from a 1.2-fold increased osteoporotic fracture risk associated with oral GC or PPI use alone. Most individual fracture sites were significantly associated with concomitant use of oral GCs and PPIs. Among concomitant users, fracture risk did not increase with higher daily dose or duration of PPI use. CONCLUSIONS: There was an interaction in the risk of osteoporotic fractures with concomitant use of oral GCs and PPIs. Fracture risk assessment could be considered when a patient with RA is co-prescribed oral GCs and PPIs.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Abtahi S, Driessen JHM, Burden AM, et al. Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2020. PMID: 33310727. doi:10.1136/annrheumdis-2020-218758

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。